首页> 美国卫生研究院文献>Journal of Clinical Medicine Research >Investigation of a Dipeptidyl Peptidase-4 Inhibitor/Thiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment
【2h】

Investigation of a Dipeptidyl Peptidase-4 Inhibitor/Thiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment

机译:二型糖尿病和血糖控制不良的二肽基肽酶-4抑制剂/噻唑烷二酮联合用药的研究:患者入组困难

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

BackgroundOne of the treatment options for type 2 diabetes mellitus (DM) is a combination drug (CD) that contains the dipeptidyl peptidase-4 inhibitor (DPP4I) alogliptin (AG) together with pioglitazone (PG). This CD can improve impaired insulin secretion and insulin resistance, which are the two major pathologic factors for type 2 DM, and is also expected to increase adherence to treatment. We conducted a multicenter open-label prospective study to examine the usefulness of this CD for routine management of type 2 DM.
机译:背景技术2型糖尿病(DM)的治疗选择之一是包含二肽基肽酶4抑制剂(DPP4I)阿格列汀(AG)和吡格列酮(PG)的组合药物(CD)。这种CD可改善受损的胰岛素分泌和胰岛素抵抗,这是2型DM的两个主要病理因素,并且有望增加对治疗的依从性。我们进行了一项多中心开放标签的前瞻性研究,以检查该CD对2型DM常规治疗的有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号